熱門資訊> 正文

Zenas BioPharma报告第二季度结果

2025-08-12 21:57

Zenas BioPharma, Inc. press release (NASDAQ:ZBIO): Q2 net loss of $52.2 million.
The company’s cash, cash equivalents and investments were $274.9 million.
The company expects that its cash, cash equivalents and investments, as of June 30, 2025, will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.

More on Zenas BioPharma

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Financial information for Zenas BioPharma, Inc.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。